SCHEMBL10003720

SCHEMBL10003720

CCc1cc2c(nc1NC(=O)c1ccccc1)c(OCC(F)(F)F)c(C(=O)O)n2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMO Q99835 1/20 0.39
▸ UGCG Q16739 1/20 0.37
▸ RAB9A P51151 3/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ ADORA3 P0DMS8 3/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ HTT P42858 2/20 0.36
▸ P2RX3 P56373 1/20 0.35
▸ KDM4E B2RXH2 4/20 0.35
▸ TRPA1 O75762 2/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ NR2E1 Q9Y466 1/20 0.35
▸ ATM Q13315 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10002854 0.90 P2RX3 (0.41) RAB9ANPC1ADORA3ADORA1HTT
SCHEMBL10003186 0.84 BRPF1 (0.44) RAB9ANPC1ADORA3ADORA1HTT
SCHEMBL10003290 0.83 P2RX3 (0.35) SMOUGCGRAB9ANPC1ADORA3
SCHEMBL10004367 0.83 SMO (0.62) SMOHTTMEN1KMT2AMAPT
SCHEMBL10003285 0.83 HTT (0.49) RAB9ANPC1ADORA1HTTKDM4E
SCHEMBL10004026 0.82 CACNA1G (0.38) SMOKDM4ETRPA1MEN1KMT2A
SCHEMBL10003010 0.81 HTT (0.41) SMOUGCGRAB9ANPC1HTT
SCHEMBL10004000 0.81 P2RX3 (0.41) RAB9ANPC1ADORA3ADORA1HTT
SCHEMBL10002985 0.79 SRD5A2 (0.39) SMORAB9ANPC1MEN1KMT2A
SCHEMBL10003387 0.78 NPC1 (0.40) RAB9ANPC1HTTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH SMO 1/4885UGCG 1236/4885RAB9A 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback